EGFR+ Non–Small Cell Lung Cancer: Frontline Options
2 意见
• 07/04/23
0
0
嵌入
Expert Mark Socinski, MD, shares insight on the frontline systemic therapy options available for EGFR-mutant non–small cell lung cancer treatment and considers the value of multidisciplinary care in the context of brain metastases.
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论